

NON-CME SATELLITE LUNCH SYMPOSIUM

microRNA Markers: Powerful Tools in the Risk Stratification of Thyroid Nodules

PRESENTED BY

Nicole Massoll, M.D.

Dr. Nicole Massoll is the Chief Medical Officer for Interpace Biosciences® and is a board-certified pathologist with an added qualification in cytopathology. She received her MD and Pathology training at the University of Arkansas for Medical Sciences and completed her Cytology fellowship at Shands Hospital Gainesville, Florida while working with Dr. Ernie Mazzaferri. She is a Professor in the Department of Pathology at the University of Arkansas for Medical Sciences. She is also the founder of FNAPath. Dr. Massoll is a member of the College of American Pathologists, American Thyroid Association, and Endocrine Society.



Six Continents Room (2nd floor)

Thursday, October 8, 2026

11:45 AM - 12:30 PM

This event is developed and offered by Interpace Diagnostics. This is not an official event of the Cleveland Clinic. Patient management decisions are based on the independent medical judgment of the physician and molecular test results should be taken into consideration in conjunction with all relevant imaging, clinical findings, patient and family history, as well as patient preference.

Confidence and Convenience¹⁻³

IN THE RISK STRATIFICATION OF INDETERMINATE THYROID NODULES



As Easy As 1-2-3...

ONE Integrated Test Result

- Malignancy risk clearly defined

TWO Combined Assessments

- Mutational analysis
- microRNA signatures

THREE High Performance Metrics

- 99% NPV^{1*}
- 94% PPV^{1,3*†}
- 70%-79% BCR^{3,4}

With Simple Specimen Handling

**No Refrigeration
or Ice Required[‡]**
For storage or shipping

**Light and
Temperature
Stable[‡]**

**Low Cell
Volume²**
Slides only require at
least 80-100 follicular cells



Visit thyroiddx.com

Patient management decisions are based on the independent medical judgment of the physician and molecular test results should be taken into consideration in conjunction with all relevant imaging, clinical findings, patient and family history, as well as patient preference.

[‡]3-Category performance aligned to clinical decision-making in atypia of undetermined significance (Bethesda III) and follicular neoplasm (Bethesda IV) nodules. NPV and PPV are calculated from moderate and positive thresholds, respectively.^{1,3,5}

^{*}The Finkelstein, et al. study was designed to provide a deeper analysis of microRNA expression and evaluated study samples with the inclusion of surgical outcomes, resulting in an NPV of 99% and a PPV of 96%. When aligned to commercial specimen handling and reporting, the NPV and PPV are 99% and 94%, respectively, for atypia of undetermined significance (Bethesda III) and follicular neoplasm (Bethesda IV) thyroid nodules.^{1,3,5}

[‡]Specimens can be held at room temperature for up to 6 weeks when placed within the provided collection buffer. No ice packs for shipping are needed.

References: 1. Finkelstein SD, et al. *Thyroid*. 2022;32(11):1362-1371. 2. Lupo MA, et al. *Diagn Cytopathol*. 2020;48(12):1254-1264. 3. Data on File. Interpace Diagnostics. 4. Verma T, et al. *Cancer Cytopathol*. 2024;132(9):556-563. doi:10.1002/cncy.22829. 5. Ali SZ, et al. *Thyroid*. 2023;33(9):1039-1044. doi:10.1089/thy.2023.0141.